Swiftly Meds Private Limited

Regonat (Regorafenib Tablets 40 mg) – Targeted Treatment for Advanced Cancer

What is Regonat (Regorafenib Tablets 40 mg)?
Regonat contains Regorafenib, an oral tyrosine kinase inhibitor used to treat advanced cancers, including colorectal cancer and gastrointestinal stromal tumors (GIST). By targeting multiple pathways involved in cancer cell growth, Regonat helps slow the progression of these cancers and improves patient outcomes in cases where other treatments have not been effective.

How Does Regonat Work?
Regonat works by inhibiting several kinase enzymes that promote cancer cell growth, blood vessel formation (angiogenesis), and tumor spread. Specifically, it targets pathways like VEGFR, KIT, and PDGFR, which are involved in tumor cell proliferation and metastasis. By blocking these pathways, Regorafenib slows down the growth and spread of cancer cells and prevents new blood vessel formation, which is necessary for tumor growth.

Indications:
Regonat (Regorafenib Tablets 40 mg) is indicated for:

• Metastatic colorectal cancer: For patients with advanced colorectal cancer who have failed or are intolerant to standard chemotherapy treatments.
• Gastrointestinal stromal tumors (GISTs): For patients with GISTs who have been previously treated with imatinib and sunitinib.
• Hepatocellular carcinoma (HCC): In certain patients with liver cancer who have failed other treatments.

Dosage and Administration:
The typical dose of Regonat 40 mg is 120 mg daily (3 tablets) taken orally, once a day for 21 days followed by a 7-day rest period (a 28-day treatment cycle). The treatment is continued as long as the patient is benefiting and does not experience significant side effects. Regonat should be taken with food to minimize gastrointestinal upset. The dosage may be adjusted based on individual patient tolerability and response.

Benefits of Regonat:

• Effective treatment for advanced cancers: Regonat helps manage cancers like metastatic colorectal cancer, GIST, and HCC that have not responded to other therapies.
• Oral administration: Convenient compared to intravenous chemotherapy treatments, improving patient comfort and compliance.
• Targeted therapy: Focuses on specific molecular targets involved in cancer progression, providing a more focused and effective treatment.

Side Effects:
Common side effects include:

• Fatigue
• Diarrhea
• Skin reactions (rash, hand-foot syndrome)
• Loss of appetite
• High blood pressure
• Mouth sores

Serious side effects may include:

• Liver damage: Symptoms like jaundice (yellowing of the skin or eyes), dark urine, or abdominal pain may indicate liver problems.
• Severe bleeding or clotting: Regonat can affect the blood’s ability to clot, leading to bleeding or clotting issues.
• Gastrointestinal perforation: A rare but serious complication where holes form in the digestive tract.

Precautions:
Before using Regonat, inform your healthcare provider if you have:

• Liver or kidney disease: Since Regorafenib is metabolized in the liver, patients with liver problems may need dose adjustments.
• Hypertension: Regonat may increase blood pressure and needs careful monitoring.
• History of bleeding or clotting disorders.
• Pregnancy or breastfeeding, as Regonat may harm an unborn baby and pass into breast milk.

 

Utamide 50mg Tablets (Bicalutamide)

Description: Utamide 50mg tablets contain Bicalutamide, which is an anti-androgen medication. Bicalutamide is used to treat prostate cancer by blocking the effects of male hormones (androgens, such as testosterone) on the prostate cancer cells. Since many prostate cancers rely on testosterone to grow, reducing the effects of testosterone can help slow the progression of the disease.

Indications:

• Prostate Cancer: Utamide 50mg is commonly used in the treatment of advanced prostate cancer, either alone or in combination with other treatments, such as LHRH agonists (Luteinizing Hormone-Releasing Hormone) or surgery (such as castration).

• It can also be used in hormonal therapy for prostate cancer in some cases, to control tumor growth in men with prostate cancer.

Mechanism of Action: Bicalutamide is a non-steroidal anti-androgen. It works by binding to androgen receptors in prostate cancer cells and blocking the effects of androgens like testosterone. This prevents these hormones from stimulating the growth of cancer cells in the prostate gland. As a result, the cancer growth is slowed or halted.

Dosage:

• The usual dose of Utamide 50mg is 50 mg once a day, taken orally.

• It can be taken with or without food but should be taken at the same time each day.

• Consistency is important for effectiveness, so try to take it at the same time each day.

Side Effects:

• Common side effects: Hot flashes, decreased libido, fatigue, nausea, abdominal discomfort, and breast tenderness or enlargement.

• Serious side effects: Liver issues (hepatotoxicity), shortness of breath, swelling of the legs or ankles, and signs of an allergic reaction.

• Very rare: Severe liver damage (symptoms like yellowing of the skin or eyes, dark urine, or severe abdominal pain) and changes in heart rhythm or function.

Precautions:

• Liver Function: Liver enzymes should be monitored regularly during treatment, as Bicalutamide can cause liver toxicity.

• Pregnancy and Breastfeeding: Not suitable for women, especially those who are pregnant or breastfeeding, as it can cause harm to the fetus.

• Heart Problems: Caution should be taken in patients with pre-existing heart conditions.

• Drug Interactions: Bicalutamide may interact with warfarin (a blood thinner) or other medications that affect liver metabolism, so dose adjustments may be required.

Monitoring: Regular follow-ups with your doctor are recommended to monitor liver function, prostate-specific antigen (PSA) levels, and other potential side effects.

Storage:

• Temperature: Store at room temperature, typically between 15°C and 30°C (59°F to 86°F).

• Moisture and Light: Keep in a dry place, away from direct sunlight and moisture.

• Keep out of reach of children: Ensure the medication is kept out of reach of children to avoid accidental ingestion.

•  

  • Expiration: Do not use after the expiration date marked on the packaging.

   

Invista 50 mg Tablets (Dasatinib) - Medicine Description

Brand Name: Invista
Generic Name: Dasatinib
Strength: 50 mg
Form: Tablet
Therapeutic Class: Tyrosine Kinase Inhibitor, Antineoplastic Agent

Overview:

Invista 50 mg Tablets contain Dasatinib, a potent tyrosine kinase inhibitor (TKI), used primarily in the treatment of Philadelphia chromosome-positive chronic myelogenous leukemia (Ph+ CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). Dasatinib works by inhibiting the BCR-ABL fusion protein, a key driver in the growth of cancerous cells in these conditions. It is particularly effective in patients who have developed resistance or intolerance to other treatments, such as Imatinib.

Dasatinib not only targets the BCR-ABL fusion protein but also other kinases like c-Kit, Src family kinases, and PDGFR, all of which contribute to the progression of cancer cells. By blocking the activity of these kinases, Dasatinib helps to prevent the growth and spread of cancer cells, leading to potential remission or stabilization of the disease.

Mechanism of Action:

Dasatinib is an oral tyrosine kinase inhibitor that targets and blocks the activity of the BCR-ABL fusion protein. This protein is produced by the Philadelphia chromosome, a genetic abnormality that plays a crucial role in the development of Chronic Myelogenous Leukemia (CML) and Acute Lymphoblastic Leukemia (ALL). By inhibiting BCR-ABL, Dasatinib helps prevent the uncontrolled division and survival of leukemia cells.

Dasatinib also targets other kinases such as c-Kit, PDGFR, and Src family kinases, which are implicated in cancer cell proliferation and survival. The multi-targeted action of Dasatinib contributes to its ability to inhibit leukemia cell growth and control disease progression.

Indications:

Invista 50 mg Tablets (Dasatinib) are indicated for the treatment of:

1. Chronic Myelogenous Leukemia (CML):

   • Philadelphia Chromosome-positive (Ph+) Chronic Phase CML in adults and children aged 1 year or older.
   • Accelerated Phase CML: For patients who are resistant or intolerant to other therapies, including Imatinib.
   • Blast Crisis CML: For patients who are resistant or intolerant to other treatments.

2. Acute Lymphoblastic Leukemia (ALL):

   • Philadelphia Chromosome-positive (Ph+) Acute Lymphoblastic Leukemia (ALL) in adults and children who are resistant or intolerant to other therapies.

Dosage and Administration:

The recommended dose of Invista 50 mg Tablets (Dasatinib) will vary depending on the disease being treated and the patient’s clinical response. The typical starting doses are:

1. For Chronic Myelogenous Leukemia (CML):

   • Chronic Phase: 50 mg once daily.
   • Accelerated Phase: 70 mg once daily.
   • Blast Crisis: 100 mg once daily.

2. For Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia (Ph+ ALL):

   • Initial dose: 140 mg once daily.